Mar 27, 2015, 00:00 AM by Michael Croft

PRINCETON, NJ - Mar 27, 2015 - Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that the Toxicological Sciences article, entitled “Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-throughput Toxicity Testing,” using its Simcyp® Simulator, has been selected by the Risk Assessment Specialty Section (RASS) of the Society of Toxicology (SOT) as its “Best Published Paper Advancing the Science of Risk Assessment

Mar 26, 2015, 09:05 AM by Michael Croft

Tech Crunch | This week marked Demo Day for budding companies incubated in Silicon Valley accelerator Y Combinator, which began putting out feelers for biotech startups last year and is now moving with more confidence into the biomedical field.

Mar 25, 2015, 16:00 PM by Michael Croft

Bio-IT World News Brief | Emerald Therapeutics is opening its first Emerald Cloud Lab (ECL) production facility, ECL-1, in the biotech corridor of South San Francisco. The robotics life sciences laboratory was announced last year, though plans were already underway for a move to South San Francisco. Since then, the company built a new production facility from the ground up and installed over $3 million of scientific instrumentation.  

Mar 25, 2015, 14:00 PM by Michael Croft

Mar 24, 2015, 12:30 PM by Michael Croft

Nature News | An independent committee reviewing the goals and practices of Europe's Human Brain Project (HBP) has substantially sided with critics of the effort, proposing major changes to the HBP's governance and to its central mission of creating a computer simulation of the human brain.

Mar 23, 2015, 00:00 AM by Michael Croft

PHILADELPHIA, PA, UNITED STATES - Mar 23, 2015 - The Intellectual Property and Science business of Thomson Reuters, the world’s leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report

Mar 20, 2015, 11:30 AM by Michael Croft

Bio-IT World | Horizon Discovery, a Cambridge, UK-based research supply company with a focus on gene editing experiments, has launched a free online tool to design guide RNA for CRISPR experiments.

Mar 20, 2015, 10:25 AM by Michael Croft

Bio-IT World News Brief | There is a renewed urgency to public conversations about the ethics of genome editing, thanks to the emergence of CRISPR, a gene engineering technology so effective and easy to use that scientists are racing to keep up with its potential applications.

Mar 20, 2015, 00:00 AM by Michael Croft

SHIRLEY, NY, UNITED STATES - Mar 20, 2015 - March 20, 2015-Creative BioMart, a leading supplier for reagents in the biotechnology field, today has added novel Albumin Fusion Protein Production Services to its protein expression services

Mar 20, 2015, 00:00 AM by Michael Croft

- Mar 20, 2015 - Nowadays, a number of highly potent and pharmaceutically improved heat shock protein 90 (Hsp90) inhibitors are undergoing clinical trials

Mar 19, 2015, 11:10 AM by Michael Croft

Bio-IT World | Scientists in the growing field of pharmacogenetics believe that new DNA tests can protect patients from adverse drug responses and ineffective prescriptions. Yet it's been an uphill battle to convince payers, medical centers, and clinicians to embrace these tests in mainstream medicine.

Mar 18, 2015, 10:30 AM by Michael Croft

Bio-IT World News Brief | Ginkgo Bioworks announced this morning that its synthetic biology “foundry,” an 18,000 square foot facility on the Boston waterfront designed to rapidly iterate through new prototypes of genetically modified organisms, is open for business.

Mar 18, 2015, 00:00 AM by Michael Croft

STRASBOURG, FRANCE - Mar 18, 2015 - At the Faculty of Pharmacy of the University of Strasbourg houses (France) a diverse group of research teams work at the interface between chemistry and biology

Mar 17, 2015, 12:45 PM by Michael Croft

Bio-IT World | 23andMe's new drug discovery unit isn't the next disruptive health innovation from Silicon Valley, but it is a good move for a company that should know better than anyone how to turn genetic data into real value.

Mar 17, 2015, 00:00 AM by Michael Croft

CHAPEL HILL, NC, UNITED STATES - Mar 17, 2015 - WHAT: Rho, a full-service contract research organization (CRO), will highlight its continued success in drug development strategies and services during the Outsourcing in Clinical Trials (OCT) Southeast conference, being held March 24-25 in Cary, North Carolina

Mar 17, 2015, 00:00 AM by Michael Croft

RESEARCH TRIANGLE PARK, NC - Mar 17, 2015 - Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, and the University of Florida Department of Medicine have announced an academic collaboration that will help rapidly design and develop novel drugs to inhibit the reproduction of cancer cells

Mar 17, 2015, 00:00 AM by Michael Croft

COLUMBUS, OH - Mar 17, 2015 - GenomeNext, LLC, a leader in genomic data management and integrated analysis, announced today that, through the “Intel Heads In The Clouds Challenge on Amazon Web Services (AWS)” with support from JHC Technology, and in conjunction with Nationwide Children’s Hospital, has benchmarked whole genome sequencing analysis at an unprecedented 1,000 genomes per day

Mar 13, 2015, 00:00 AM by Michael Croft

LOS ANGELES, CA - Mar 13, 2015 - Reprints Desk, Inc., a Research Solutions (OTCQB: RSSS) company and top-rated document delivery supplier for scientific, technical and medical (STM) information, has announced the immediate full-text availability of the article The Ultimate Sophistication: Reprints Desk Launches its Article Galaxy Widget, created by independent research and advisory firm Outsell, Inc

Mar 12, 2015, 14:00 PM by Michael Croft

Mar 12, 2015, 00:00 AM by Michael Croft

Forbes | 23andMe CEO and Founder Anne Wojcicki 23andMe, the Google-backed personal genetics startup, will no longer just sell tests to consumers, or genetic data to pharmaceutical companies. This morning, it announced that it plans to start inventing medicines itself. It's not just talk. The company has hired Richard Scheller, who led drug discovery at Genentech.